EGFR and cancer: Hossein-Nejad-Ariani et al. demonstrated that the peptide analog 22 (YHWYGYTPENVI) (P22) exhibits higher uptake in cancer cells than the initial peptide GE11 (123-fold and 47-fold in MDA-MB-468 and MDA-MB-231 cell lines, respectively).18 P22 would therefore be the best candidate for targeting all types of cancers overexpressing EGFR, like HNCs.